Alterations of brain circuits in Down syndrome murine models

Journal of Chemical Neuroanatomy

Volumn 42, Issue 4, 2011, Pages 317-326

  Gotti, Stefano ^a,b   Caricati, Egidio ^a,b   Panzica, GianCarlo ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Neuroscience Institute Cavalieri Ottolenghi   (Italy)

Author keywords

Mental retardation; Mouse models; Trisomy 21; Ts1Cje; Ts65Dn

Indexed keywords

NEUROTRANSMITTER;

ANIMAL MODEL; AUTONOMIC NERVOUS SYSTEM; BRAIN CORTEX; CEREBELLUM; CHOLINERGIC SYSTEM; CHROMOSOME 10; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 21; DOWN SYNDROME; FOREBRAIN; GENOTYPE PHENOTYPE CORRELATION; GRANULE CELL; HIPPOCAMPUS; LATERAL BRAIN VENTRICLE; MONOAMINERGIC SYSTEM; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NITRERGIC SYSTEM; NONHUMAN; NORADRENERGIC NERVE; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; REVIEW; VASOPRESSINERGIC SYSTEM;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HUMANS; MICE; MICE, TRANSGENIC; NERVE NET;

EID: 80555131100     PISSN: 08910618     EISSN: 18736300     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2011.09.002     Document Type: Review

References (123)

1. Aldridge K., Reeves R.H., Olson L.E., Richtsmeier J.T. Differential effects of trisomy on brain shape and volume in related aneuploid mouse models. Am. J. Med. Genet. A 2007, 143A:1060-1070.
2. Alves-Sampaio A., Troca-Marin J.A., Montesinos M.L. NMDA-mediated regulation of DSCAM dendritic local translation is lost in a mouse model of Down's syndrome. J. Neurosci. 2010, 30:13537-13548.
3. Antonarakis S.E., Epstein C.J. The challenge of Down syndrome. Trends Mol. Med. 2006, 12:473-479.
4. Baxter L.L., Moran T.H., Richtsmeier J.T., Troncoso J., Reeves R.H. Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum. Mol. Genet. 2000, 9:195-202.
5. Belichenko N.P., Belichenko P.V., Kleschevnikov A.M., Salehi A., Reeves R.H., Mobley W.C. The Down syndrome critical region is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J. Neurosci. 2009, 29:5938-5948.
6. Belichenko P.V., Kleschevnikov A.M., Salehi A., Epstein C.J., Mobley W.C. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J. Comp. Neurol. 2007, 504:329-345.
7. Belichenko P.V., Masliah E., Kleschevnikov A.M., Villar A.J., Epstein C.J., Salehi A., Mobley W.C. Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 2004, 480:281-298.
8. Bianchi P., Ciani E., Contestabile A., Guidi S., Bartesaghi R. Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol. 2010, 20:106-118.
9. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., Fernandez M., Giuliani A., Calza L., Bartesaghi R. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 2010, 30:8769-8779.
10. Bimonte-Nelson H.A., Hunter C.L., Nelson M.E., Granholm A.C. Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav. Brain Res. 2003, 139:47-57.
11. Bovicelli L., Orsini L.F., Rizzo N., Montacuti V., Bacchetta M. Reproduction in Down syndrome. Obstet. Gynecol. 1982, 59:13S-17S.
12. Branchi I., Bichler Z., Minghetti L., Delabar J.M., Malchiodi-Albedi F., Gonzalez M.C., Chettouh Z., Nicolini A., Chabert C., Smith D.J., Rubin E.M., Migliore-Samour D., Alleva E. Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration. J. Neuropathol. Exp. Neurol. 2004, 63:429-440.
13. Casanova M.F., Walker L.C., Whitehouse P.J., Price D.L. Abnormalities of the nucleus basalis in Down's syndrome. Ann. Neurol. 1985, 18:310-313.
14. Castagna C., Viglietti-Panzica C., Panzica G.C. Protein S100 immunoreactivity in glial cells and neurons of the Japanese quail brain. J. Chem. Neuroanat. 2003, 25:195-212.
15. Cataldo A.M., Petanceska S., Peterhoff C.M., Terio N.B., Epstein C.J., Villar A., Carlson E.J., Staufenbiel M., Nixon R.A. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of Down syndrome. J. Neurosci. 2003, 23:6788-6792.
16. Chabert C., Jamon M., Cherfouh A., Duquenne V., Smith D.J., Rubin E., Roubertoux P.L. Functional analysis of genes implicated in Down syndrome: 1. Cognitive abilities in mice transpolygenic for Down syndrome chromosomal region-1 (DCR-1). Behav. Genet. 2004, 34:559-569.
17. Clark S., Schwalbe J., Stasko M.R., Yarowsky P.J., Costa A.C. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp. Neurol. 2006, 200:256-261.
18. Collacott R.A. Epilepsy, dementia and adaptive behaviour in Down's syndrome. Intellect. Disabil. Res. 1993, 37:153-160.
19. Contestabile A., Fila T., Bartesaghi R., Contestabile A., Ciani E. Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. J. Neurochem. 2006, 97:515-526.
20. Contestabile A., Fila T., Ceccarelli C., Bonasoni P., Bonapace L., Santini D., Bartesaghi R., Ciani E. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
21. Contestabile A., Benfenati F., Gasparini L. Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome. Prog. Neurobiol. 2010, 91:1-22.
22. Cooper J.D., Salehi A., Delcroix J.D., Howe C.L., Belichenko P.V., Chua-Couzens J., Kilbridge J.F., Carlson E.J., Epstein C.J., Mobley W.C. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10439-10444.
23. Davisson M.T. Mouse models of Down syndrome. Drug Discov. Today: Dis. Models 2005, 2:103-109.
24. Davisson M.T., Schmidt C., Akeson E.C. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog. Clin. Biol. Res. 1990, 360:263-280.
25. Davisson M.T., Schmidt C., Reeves R.H., Irving N.G., Akeson E.C., Harris B.S., Bronson R.T. Segmental trisomy as a mouse model for Down syndrome. Prog. Clin. Biol. Res. 1993, 384:117-133.
26. de Vente J. cGMP: a second messenger for acetylcholine in the brain?. Neurochem. Int. 2004, 45:799-812.
27. Delabar J.M., Theophile D., Rahmani Z., Chettouh Z., Blouin J.L., Prieur M., Noel B., Sinet P.M. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur. J. Hum. Genet. 1993, 1:114-124.
28. Demas G.E., Nelson R.J., Krueger B.K., Yarowsky P.J. Spatial memory deficits in segmental trisomic Ts65Dn mice. Behav. Brain Res. 1996, 82:85-92.
29. Demas G.E., Nelson R.J., Krueger B.K., Yarowsky P.J. Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice. Behav. Brain Res. 1998, 90:199-201.
30. Dierssen M., Benavides-Piccione R., Martinez-Cue C., Estivill X., Florez J., Elston G.N., DeFelipe J. Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: effects of environmental enrichment. Cereb. Cortex 2003, 13:758-764.
31. Dierssen M., Fillat C., Crnic L., Arbones M., Florez J., Estivill X. Murine models for Down syndrome. Physiol. Behav. 2001, 73:859-871.
32. Dierssen M., Vallina I.F., Baamonde C., Garcia-Calatayud S., Lumbreras M.A., Florez J. Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome. Brain Res. 1997, 749:238-244.
33. Down J.L.H. Observations on an ethnic classification of idiots. J. Mental Sci. 1867, 13:121-123.
34. Ema M., Ikegami S., Hosoya T., Mimura J., Ohtani H., Nakao K., Inokuchi K., Katsuki M., Fujii-Kuriyama Y. Mild impairment of learning and memory in mice overexpressing the mSim2 gene located on chromosome 16: an animal model of Down's syndrome. Hum. Mol. Genet. 1999, 8:1409-1415.
35. Epstein C.J. Developmental genetics. Experientia 1986, 42:1117-1128.
36. Epstein C.J., Berger C.N., Carlson E.J., Chan P.H., Huang T.T. Models for Down syndrome: chromosome 21-specific genes in mice. Molecular Genetics of Chromosome 21 and Down Syndrome 1990, 215-232. Wiley-Liss, New York. D. Patterson, C.J. Epstein (Eds.).
37. Epstein C.J., Cox D.R., Epstein L.B. Mouse trisomy 16: an animal model of human trisomy 21 (Down syndrome). Ann. N.Y. Acad. Sci. 1985, 450:157-168.
38. Escorihuela R.M., Fernandez-Teruel A., Vallina I.F., Baamonde C., Lumbreras M.A., Dierssen M., Tobena A., Florez J. A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci. Lett. 1995, 199:143-146.
39. Gahtan E., Auerbach J.M., Groner Y., Segal M. Reversible impairment of long-term potentiation in transgenic Cu/Zn-SOD mice. Eur. J. Neurosci. 1998, 10:538-544.
40. Galante M., Jani H., Vanes L., Daniel H., Fisher E.M., Tybulewicz V.L., Bliss T.V., Morice E. Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Hum. Mol. Genet. 2009, 18:1449-1463.
41. Galdzicki Z., Siarey R., Pearce R., Stoll J., Rapoport S.I. On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models. Brain Res. Rev. 2001, 35:115-145.
42. Gardiner K., Costa A.C. The proteins of human chromosome 21. Am. J. Med. Genet. C: Semin. Med. Genet. 2006, 142C:196-205.
43. Gardiner K., Fortna A., Bechtel L., Davisson M.T. Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 2003, 318:137-147.
44. Gerlai R., Friend W., Becker L., O'Hanlon D., Marks A., Roder J. Female transgenic mice carrying multiple copies of the human gene for S100 beta are hyperactive. Behav. Brain Res. 1993, 55:51-59.
45. Gotti, S., Caricati, E., Viglietti-Panzica, C., Panzica, G., 2005. Nitrinergic and Cholinergic System in the Tegmental Nuclei of a Murine Model (Ts65Dn mice) for Down Syndrome. Program No. 584.8. Neuroscience Meeting Planner. Society for Neuroscience, Washington, DC (Online).
46. Gotti S., Chiavegatto S., Sica M., Viglietti-Panzica C., Nelson R.J., Panzica G. Alteration of NO-producing system in the basal forebrain and hypothalamus of Ts65Dn mice: an immunohistochemical and histochemical study of a murine model for Down syndrome. Neurobiol. Dis. 2004, 16:563-571.
47. Granholm A.-C.E., Sanders L.A., Crnic L.S. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp. Neurol. 2000, 161:647-663.
48. Granholm A.C., Sanders L., Seo H., Lin L., Ford K., Isacson O. Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome. Hippocampus 2003, 13:905-914.
49. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:7611-7615.
50. Haydar T.F., Blue M.E., Molliver M.E., Krueger B.K., Yarowsky P.J. Consequences of trisomy 16 for mouse brain development: corticogenesis in a model of Down syndrome. J. Neurosci. 1996, 16:6175-6182.
51. Haydar T.F., Nowakowski R.S., Yarowsky P.J., Krueger B.K. Role of founder cell deficit and delayed neuronogenesis in microencephaly of the trisomy 16 mouse. J. Neurosci. 2000, 20:4156-4164.
52. Hardy J., Irving N., Kessling A. Down on chromosome 21?. Trends Neurosci. 1989, 12:209-210.
53. Harris-Cerruti C., Kamsler A., Kaplan B., Lamb B., Segal M., Groner Y. Functional and morphological alterations in compound transgenic mice overexpressing Cu/Zn superoxide dismutase and amyloid precursor protein. Eur. J. Neurosci. 2004, 19:1174-1190. (correction).
54. Hassold T.J., Jacobs P.A. Trisomy in man. Annu. Rev. Genet. 1984, 18:69-97.
55. Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.S., Toyoda A., Ishii K., Totoki Y., Choi D.K., Groner Y., Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J., Schibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brant P., Scharfe M., Schon O., Desario A., Reichelt J., Kauer G., Blocker H., Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E., Haaf T., Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.L. The DNA sequence of human chromosome 21. Nature 2000, 405:311-319.
56. Hewitt C.A., Ling K.H., Merson T.D., Simpson K.M., Ritchie M.E., King S.L., Pritchard M.A., Smyth G.K., Thomas T., Scott H.S., Voss A.K. Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome. PLoS One 2010, 5:e11561.
57. Hill J.M., Ades A.M., McCune S.K., Sahir N., Moody E.M., Abebe D.T., Crnic L.S., Brenneman D.E. Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome. Exp. Neurol. 2003, 183:56-65.
58. Holtzman D.M., Santucci D., Kilbridge J., Chua-Couzens J., Fontana D.J., Daniels S.E., Johnson R.M., Chen K., Sun Y., Carlson E., Alleva E., Epstein C.J., Mobley W.C. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13333-13338.
59. Hook E.B. Unbalanced Robertsonian translocations associated with Down's syndrome or Patau's syndrome: chromosome subtype, proportion inherited, mutation rates, and sex ratio. Hum. Genet. 1981, 59:235-239.
60. Hunter C.L., Bachman D., Granholm A.C. Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann. Neurol. 2004, 56:675-688.
61. Hunter C.L., Bimonte-Nelson H.A., Nelson M., Eckman C.B., Granholm A.C. Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. Neurobiol. Aging 2004, 25:873-884.
62. Hunter C.L., Isacson O., Nelson M., Bimonte-Nelson H., Seo H., Lin L., Ford K., Kindy M.S., Granholm A.C. Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome. Neurosci. Res. 2003, 45:437-445.
63. Insausti A.M., Megias M., Crespo D., Cruz-Orive L.M., Dierssen M., Vallina I.F., Insausti R., Florez J. Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome. Neurosci. Lett. 1998, 253:175-178.
64. Ishihara K., Amano K., Takaki E., Ebrahim A.S., Shimohata A., Shibazaki N., Inoue I., Takaki M., Ueda Y., Sago H., Epstein C.J., Yamakawa K. Increased lipid peroxidation in Down's syndrome mouse models. J. Neurochem. 2009, 110:1965-1976.
65. Ishihara K., Amano K., Takaki E., Shimohata A., Sago H., Epstein C.J., Yamakawa K. Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb. Cortex 2010, 20:1131-1143.
66. Kahlem P., Sultan M., Herwig R., Steinfath M., Balzereit D., Eppens B., Saran N.G., Pletcher M.T., South S.T., Stetten G., Lehrach H., Reeves R.H., Yaspo M.L. Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of Down syndrome. Genome Res. 2004, 14:1258-1267.
67. Kapranov P., Cawley S.E., Drenkow J., Bekiranov S., Strausberg R.L., Fodor S.P., Gingeras T.R. Large-scale transcriptional activity in chromosomes 21 and 22. Science 2002, 296:916-919.
68. Klein S.L., Kriegsfeld L.J., Hairston J.E., Rau V., Nelson R.J., Yarowsky P.J. Characterization of sensorimotor performance, reproductive and aggressive behaviors in segmental trisomic 16 (Ts65Dn) mice. Physiol. Behav. 1996, 60:1159-1164.
69. Kola I., Hertzog P.J. Down syndrome and mouse models. Curr. Opin. Genet. Dev. 1998, 8:316-321.
70. Korenberg J.R., Chen X.N., Schipper R., Sun Z., Gonsky R., Gerwehr S., Carpenter N., Daumer C., Dignan P., Disteche C., et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:4997-5001.
71. Korenberg J.R., Kawashima H., Pulst S.M., Ikeuchi T., Ogasawara N., Yamamoto K., Schonberg S.A., West R., Allen L., Magenis E., et al. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am. J. Hum. Genet. 1990, 47:236-246.
72. Labudova O., Fang-Kircher S., Cairns N., Moenkemann H., Yeghiazaryan K., Lubec G. Brain vasopressin levels in Down syndrome and Alzheimer's disease. Brain Res. 1998, 806:55-59.
73. Lejeune J., Gautier M., Turpin R. Study of somatic chromosomes from 9 mongoloid children. C. R. Hebd. Seances Acad. Sci. 1959, 248:1721-1722.
74. Lockrow J., Boger H., Gerhardt G., Aston-Jones G., Bachman D., Granholm A.C. A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. J. Alzheimers Dis. 2011, 23:471-489.
75. Lockrow J., Prakasam A., Huang P., Bimonte-Nelson H., Sambamurti K., Granholm A.C. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp. Neurol. 2009, 216:278-289.
76. Lomoio S., Scherini E., Necchi D. Beta-amyloid overload does not directly correlate with SAPK/JNK activation and tau protein phosphorylation in the cerebellar cortex of Ts65Dn mice. Brain Res. 2009, 1297:198-206.
77. Lorenzi H.A., Reeves R.H. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res. 2006, 1104:153-159.
78. Macri J.N., Spencer K., Aitken D., Garver K., Buchanan P.D., Muller F., Boue A. First-trimester free beta (hCG) screening for Down syndrome. Prenat. Diagn. 1993, 13:557-562.
79. Mann D.M., Yates P.O., Marcyniuk B. Changes in Alzheimer's disease in the magnocellular neurones of the supraoptic and paraventricular nuclei of the hypothalamus and their relationship to the noradrenergic deficit. Clin. Neuropathol. 1985, 4:127-134.
80. Mao R., Wang X., Spitznagel E.L., Frelin L.P., Ting J.C., Ding H., Kim J.W., Ruczinski I., Downey T.J., Pevsner J. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biol. 2005, 6:R107.
81. Megias M., Verduga R., Dierssen M., Florez J., Insausti R., Crespo D. Cholinergic, serotonergic and catecholaminergic neurons are not affected in Ts65Dn mice. Neuroreport 1997, 8:3475-3478.
82. Moore C.S., Hawkins C., Franca A., Lawler A., Devenney B., Das I., Reeves R.H. Increased male reproductive success in Ts65Dn Down syndrome mice. Mamm. Genome 2010, 21:543-549.
83. Morice E., Andreae L.C., Cooke S.F., Vanes L., Fisher E.M., Tybulewicz V.L., Bliss T.V. Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome. Learn. Mem. 2008, 15:492-500.
84. Nadal M., Mila M., Pritchard M., Mur A., Pujals J., Blouin J.L., Antonarakis S.E., Ballesta F., Estivill X. YAC and cosmid FISH mapping of an unbalanced chromosomal translocation causing partial trisomy 21 and Down syndrome. Hum. Genet. 1996, 98:460-466.
85. Nadel L. Neural and cognitive development in Down syndrome. Down Syndrome: Living and Learning in the Community 1994, 107-114. Wiley-Liss, New York. L. Nadel, D. Rosenthal (Eds.).
86. Necchi D., Lomoio S., Scherini E. Axonal abnormalities in cerebellar Purkinje cells of the Ts65Dn mouse. Brain Res. 2008, 1238:181-188.
87. Nelson R.J., Demas G.E., Huang P.L., Fishman M.C., Dawson V.L., Dawson T.M., Snyder S.H. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 1995, 378:383-386.
88. Newby D., Aitken D.A., Crossley J.A., Howatson A.G., Macri J.N., Connor J.M. Biochemical markers of trisomy 21 and the pathophysiology of Down's syndrome pregnancies. Prenat. Diagn. 1997, 17:941-951.
89. O'Doherty A., Ruf S., Mulligan C., Hildreth V., Errington M.L., Cooke S., Sesay A., Modino S., Vanes L., Hernandez D., Linehan J.M., Sharpe P.T., Brandner S., Bliss T.V., Henderson D.J., Nizetic D., Tybulewicz V.L., Fisher E.M. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005, 309:2033-2037.
90. Olson L.E., Roper R.J., Baxter L.L., Carlson E.J., Epstein C.J., Reeves R.H. Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev. Dyn. 2004, 230:581-589.
91. Olson L.E., Roper R.J., Sengstaken C.L., Peterson E.A., Aquino V., Galdzicki Z., Siarey R., Pletnikov M., Moran T.H., Reeves R.H. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum. Mol. Genet. 2007, 16:774-782.
92. Panzica G.C., Garzino A. Anatomically specific colocalization of NADPH-diaphorase and choline acetyltransferase in the quail brainstem. Neurosci. Lett. 1997, 231:151-154.
93. Panzica G.C., Bassi L., Gotti S. Vasopressinergic system and aging in the female Ts65Dn mouse, a murine model for Down syndrome. Front. Neuroendocrinol. 2006, 27:2.
94. Patterson D. The causes of Down syndrome. Sci. Am. 1987, 257:52-57. 60.
95. Patterson D., Costa A.C. Down syndrome and genetics - a case of linked histories. Nat. Rev. Genet. 2005, 6:137-147.
96. Pereira P.L., Magnol L., Sahun I., Brault V., Duchon A., Prandini P., Gruart A., Bizot J.C., Chadefaux-Vekemans B., Deutsch S., Trovero F., Delgado-Garcia J.M., Antonarakis S.E., Dierssen M., Herault Y. A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of Down syndrome. Hum. Mol. Genet. 2009, 18:4756-4769.
97. Perez-Cremades D., Hernandez S., Blasco-Ibanez J.M., Crespo C., Nacher J., Varea E. Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. J. Neural Transm. 2010, 117:445-455.
98. Pollonini G., Gao V., Rabe A., Palminiello S., Albertini G., Alberini C.M. Abnormal expression of synaptic proteins and neurotrophin-3 in the Down syndrome mouse model Ts65Dn. Neuroscience 2008, 156:99-106.
99. Ramakrishna N., Meeker H.C., Li S., Brown W.T., Rao R., El Idrissi A. Upregulation of beta-catenin expression in Down syndrome model Ts65Dn mouse brain. Neuroscience 2009, 161:451-458.
100. Reeves R.H., Irving N.G., Moran T.H., Wohn A., Kitt C., Sisodia S.S., Schmidt C., Bronson R.T., Davisson M.T. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-184.
101. Richtsmeier J.T., Zumwalt A., Carlson E.J., Epstein C.J., Reeves R.H. Craniofacial phenotypes in segmentally trisomic mouse models for Down syndrome. Am. J. Med. Genet. 2002, 107:317-324.
102. Rickmann M., Wolff J.R. S100 protein expression in subpopulations of neurons of rat brain. Neuroscience 1995, 67:977-991.
103. Roizen N.J., Patterson D. Down's syndrome. Lancet 2003, 361:1281-1289.
104. Roper R.J., Baxter L.L., Saran N.G., Klinedinst D.K., Beachy P.A., Reeves R.H. Defective cerebellar response to mitogenic Hedgehog signaling in Down [corrected] syndrome mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1452-1456.
105. Roubertoux P.L., Carlier M. Mouse models of cognitive disabilities in trisomy 21 (Down syndrome). Am. J. Med. Genet. C: Semin. Med. Genet. 2010, 154C:400-416.
106. Roubertoux P.L., Kerdelhue B. Trisomy 21: from chromosomes to mental retardation. Behav. Genet. 2006, 36:346-354.
107. Rueda N., Mostany R., Pazos A., Florez J., Martinez-Cue C. Cell proliferation is reduced in the dentate gyrus of aged but not young Ts65Dn mice, a model of Down syndrome. Neurosci. Lett. 2005, 380:197-201.
108. Sago H., Carlson E.J., Smith D.J., Kilbridge J., Rubin E.M., Mobley W.C., Epstein C.J., Huang T.T. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6256-6261.
109. Sago H., Carlson E.J., Smith D.J., Rubin E.M., Crnic L.S., Huang T.T., Epstein C.J. Genetic dissection of region associated with behavioral abnormalities in mouse models for Down syndrome. Pediatr. Res. 2000, 48:606-613.
110. Salehi A., Delcroix J.D., Belichenko P.V., Zhan K., Wu C., Valletta J.S., Takimoto-Kimura R., Kleschevnikov A.M., Sambamurti K., Chung P.P., Xia W., Villar A., Campbell W.A., Kulnane L.S., Nixon R.A., Lamb B.T., Epstein C.J., Stokin G.B., Goldstein L.S., Mobley W.C. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006, 51:29-42.
111. Saran N.G., Pletcher M.T., Natale J.E., Cheng Y., Reeves R.H. Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Hum. Mol. Genet. 2003, 12:2013-2019.
112. Seidl R., Kaehler S.T., Prast H., Singewald N., Cairns N., Gratzer M., Lubec G. Serotonin (5-HT) in brains of adult patients with Down syndrome. J. Neural Transm. Suppl. 1999, 57:221-232.
113. Seo H., Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp. Neurol. 2005, 193:469-480.
114. Seregaza Z., Roubertoux P.L., Jamon M., Soumireu-Mourat B. Mouse models of cognitive disorders in trisomy 21: a review. Behav. Genet. 2006, 36:387-404.
115. Sheppard O., Plattner F., Rubin A., Slender A., Linehan J.M., Brandner S., Tybulewicz V.L., Fisher E.M., Wiseman F.K. Altered regulation of tau phosphorylation in a mouse model of Down syndrome aging. Neurobiol. Aging 2011, [Epub ahead of print].
116. Shinohara T., Tomizuka K., Miyabara S., Takehara S., Kazuki Y., Inoue J., Katoh M., Nakane H., Iino A., Ohguma A., Ikegami S., Inokuchi K., Ishida I., Reeves R.H., Oshimura M. Mice containing a human chromosome 21 model behavioral impairment and cardiac anomalies of Down's syndrome. Hum. Mol. Genet. 2001, 10:1163-1175.
117. Shukkur E.A., Shimohata A., Akagi T., Yu W., Yamaguchi M., Murayama M., Chui D., Takeuchi T., Amano K., Subramhanya K.H., Hashikawa T., Sago H., Epstein C.J., Takashima A., Yamakawa K. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum. Mol. Genet. 2006, 15:2752-2762.
118. Siarey R.J., Carlson E.J., Epstein C.J., Balbo A., Rapoport S.I., Galdzicki Z. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 1999, 38:1917-1920.
119. Smith D.J., Zhu Y., Zhang J., Cheng J.F., Rubin E.M. Construction of a panel of transgenic mice containing a contiguous 2-Mb set of YAC/P1 clones from human chromosome 21q22.2. Genomics 1995, 27:425-434.
120. Teipel S.J., Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav. Genet. 2006, 36:405-415.
121. Villar A.J., Belichenko P.V., Gillespie A.M., Kozy H.M., Mobley W.C., Epstein C.J. Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12. Mamm. Genome 2005, 16:79-90.
122. Yates C.M., Simpson J., Gordon A., Maloney A.F., Allison Y., Ritchie I.M., Urquhart A. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res. 1983, 280:119-126.
123. Yu T., Li Z., Jia Z., Clapcote S.J., Liu C., Li S., Asrar S., Pao A., Chen R., Fan N., Carattini-Rivera S., Bechard A.R., Spring S., Henkelman R.M., Stoica G., Matsui S., Nowak N.J., Roder J.C., Chen C., Bradley A., Yu Y.E. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum. Mol. Genet. 2010, 19:2780-2791.